Marksans Pharma share price
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Formerly Tasc Pharmaceuticals
Last close ₹286.90down ₹7.55 (2.56%)BSE ₹286.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹294.45.
52-week range of traded prices to 23 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹13,001 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 25.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 4.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 12 Aug 2026
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 14,14,61953.0% delivered
Results
Standalone, as consolidated accounts are on record for only 9 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 12 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹321 Crdown 11.17%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹69 Crdown 24.90%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 21.5%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2020, the company's revenue for that year, ₹433 Cr, differs from its quarters added, ₹424 Cr.
| ₹ crore | Sep 2024Filed 12 Nov | Dec 2024Filed 11 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 13 Nov | Dec 2025Filed 5 Feb | Mar 2026Filed 26 May | Jun 2026Filed 12 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 309 | 312 | 299 | 320 | 320 | 340 | 362 | 321 |
| Net profit | 63 | 55 | 38 | 48 | 100 | 61 | 92 | 69 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 20.5% | 17.8% | 12.6% | 15.0% | 31.1% | 17.9% | 25.4% | 21.5% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical Formulation, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2020: days before it are of the company before the change.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 57% of 2,480 trading days over the last 10 years.
LowestHighest
Its median20.9Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 75% of 1,884 trading days since Nov 2018.
LowestHighest
Its median3.2Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.16.9
At or below today's level on 70% of 1,884 trading days since Nov 2018.
LowestHighest
Its median9.8Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 62% of 2,465 trading days over the last 10 years.
LowestHighest
Its median0.28%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −28.9% | +60.0% | −55.9% | 0.6% |
| 3 years | +31.1% | +43.0% | −8.6% | 0.4% |
| 5 years | +26.2% | +22.6% | +2.6% | 0.5% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual funds holding it
26 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 9 of the 15 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 4
- CutCut. Funds that held fewer shares than at the end of the month before.
- 11
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 9
| Fund | |||
|---|---|---|---|
 Bandhan Small Cap FundBandhan Mutual Fund | 34,21,739 | 0.31% | ₹110.3 Cr |
 UTI Small Cap FundUTI Mutual Fund | 29,72,150 | 1.83% | ₹95.8 Cr |
 Kotak MNC FundKotak Mahindra Mutual Fund | 20,00,000 | 2.87% | ₹64.5 Cr |
| Kotak Special Opportunities FundKotak Mahindra Mutual Fund | 15,29,807 | 2.57% | ₹49.3 Cr |
| UTI Large & Mid Cap FundUTI Mutual Fund | 14,02,958 | 0.73% | ₹45.2 Cr |
| UTI Aggressive Hybrid FundUTI Mutual Fund | 12,04,953 | 0.60% | ₹38.8 Cr |
| UTI Healthcare FundUTI Mutual Fund | 10,00,000 | 2.25% | ₹32.2 Cr |
| Kotak Healthcare FundKotak Mahindra Mutual Fund | 6,25,000 | 2.44% | ₹20.1 Cr |
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 5,82,076 | 0.78% | ₹18.8 Cr |
| UTI Multi Cap FundUTI Mutual Fund | 5,00,624 | 0.76% | ₹16.1 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Marksans Pharma in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Eris LifesciencesERIS | 15,199 | 23.6 | 3.9 | 15.3 | +9.7% | +66.4% | 19.1% | 13.8% | 0.66% |
 AstraZeneca Pharma IndiaASTRAZEN | 14,971 | 88.3 | 17.2 | 63.2 | +31.1% | −7.5% | 20.6% | 24.4% | 0.60% |
 Jubilant PharmovaJUBLPHARMA | 14,945 | 42.4 | 2.1 | 13.9 | +16.3% | −23.5% | 5.3% | 7.3% | 0.53% |
 Alembic PharmaceuticalsAPLLTD | 14,941 | 21.6 | 2.6 | 13.8 | +14.1% | +14.6% | 12.7% | 11.8% | 1.58% |
 Concord BiotechCONCORDBIO | 12,860 | 46.7 | 6.4 | 33.1 | −6.7% | −22.7% | 14.4% | 15.6% | 0.61% |
 CORONA RemediesCORONA | 12,545 | 63.0 | 16.8 | 39.9 | – | – | 26.6% | 30.9% | 0.49% |
 Akums Drugs and PharmaceuticalsAKUMS | 10,530 | 36.1 | 3.2 | 15.7 | +9.2% | −14.6% | 9.2% | 12.0% | 0.45% |
 Strides Pharma ScienceSTAR | 9,354 | 15.2 | 3.0 | 11.5 | +7.3% | – | 21.7% | 15.1% | 0.49% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹0.90 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 20 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.90 |
| 1 Aug 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.80 |
| 17 Sep 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.60 |
| 7 Jun 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 19 Aug 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.25 |
| 15 Sep 2021 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.25 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
1 Sep · Analysts
Aug 2026
Marksans Pharma share price by year
Each calendar year to 2025.Marksans Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 180.29 | −39.2% | 304.65 | 164.06 |
| 2024 | 296.65 | +84.1% | 353.40 | 132.95 |
| 2023 | 161.10 | +176.6% | 170.65 | 58.30 |
| 2022 | 58.25 | −3.2% | 64.05 | 39.45 |
| 2021 | 60.15 | −0.8% | 94.55 | 49.35 |
| 2020 | 60.65 | +263.2% | 64.90 | 10.45 |
| 2019 | 16.70 | −40.0% | 28.20 | 12.60 |
| 2018 | 27.85 | −30.3% | 48.75 | 24.65 |
| 2017 | 39.95 | +0.3% | 56.45 | 35.20 |
| 2016 | 39.85 | −61.9% | 104.60 | 34.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 292.00 | 295.35 | 282.70 | 286.90 | 287.30 | 14,14,619 | 53.0% |
| 22 Oct 2026 | 294.00 | 298.00 | 291.25 | 294.45 | 294.52 | 8,17,786 | 42.8% |
| 21 Oct 2026 | 304.65 | 306.75 | 293.60 | 298.15 | 298.28 | 13,85,441 | 47.8% |
| 19 Oct 2026 | 311.00 | 314.50 | 302.00 | 303.05 | 307.30 | 8,17,392 | 43.9% |
| 16 Oct 2026 | 308.10 | 313.50 | 306.00 | 311.00 | 310.02 | 7,67,998 | 44.4% |
| 15 Oct 2026 | 314.20 | 315.10 | 306.55 | 307.85 | 310.58 | 6,81,887 | 42.5% |
| 14 Oct 2026 | 315.00 | 320.90 | 312.35 | 314.15 | 316.82 | 5,92,331 | 45.2% |
| 13 Oct 2026 | 316.95 | 318.00 | 309.80 | 317.25 | 313.80 | 10,11,092 | 45.2% |
| 12 Oct 2026 | 310.00 | 318.00 | 309.00 | 316.40 | 314.12 | 8,22,584 | 45.3% |
| 9 Oct 2026 | 308.50 | 316.40 | 308.00 | 309.10 | 311.34 | 11,40,146 | 36.3% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 15 Jan 2016 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 11 Mar 2008 | Split | 0.1000 | Each share became 10. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- Marksans Pharma Limited
- NSE symbol
- MARKSANS
- BSE code
- 524404
- ISIN
- INE750C01026
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Feb 1994 on BSE, Jan 2002 on NSE
- Face value
- ₹1
- Former symbols
- TASCPHARMA
- CIN
- L24110MH1992PLC066364
- Corporate identity number, the registrar of companies' code for it